Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, based on the preliminary voting results provided by its proxy solicitors following the Company's 2023 General Meeting of Shareholders (the “General Meeting”), Amarin shareholders have voted to elect all seven of Sarissa's nominees and remove Per Wold-Olsen as Chairman of the Board of Directors, effective immediately.

Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders

DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.

Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand

DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today issued the following statement in response to Sarissa's latest misstatements regarding the Company's management compensation:

Amarin Sets the Record Straight on Sarissa's Latest Misstatements

Presentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress Presentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress

Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa is appalled at this latest act of betrayal of the shareholders by the Amarin board. Sarissa has been urging the Amarin board to release the results of the proxy contest for several days. The board, however, has steadfastly refused, leaving Amarin shareholders to twist in the wind.

Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives

Amarin and Sarissa are engaged in a bitter proxy war. Amarin has problems, but Sarissa doesn't have clear solutions.

The Amarin Proxy War: Amarin Has Problems, But Sarissa Doesn't Offer Solutions

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is scheduled to participate at the Cowen Annual Health Care Conference.

Amarin to Present at Cowen's 43rd Annual Health Care Conference

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa urges Amarin shareholders to vote “FOR” change TODAY to remake the Amarin board for shareholders at our upcoming meeting. Given the voting logistics for the meeting, votes must be submitted TODAY in order to be received in time to be counted for tomorrow's formal deadline.

Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote “FOR” Change

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's fourth quarter and year end 2022 financial results on Wednesday, March 1st , 2023 at 8:00 a.m. ET.

Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa urges Amarin shareholders to vote “FOR” necessary change at our upcoming shareholder meeting. The outcome of this meeting will significantly affect the future of Amarin.

Sarissa Capital Urges Amarin Shareholders to Vote “FOR” Necessary Change

The NEW Amarin and NEW Board is On the Right Track – Leading Independent Experts, ISS and Glass Lewis, Agree that Sarissa Representation is Not Warranted

Amarin Urges Shareholders to Vote “Against” Sarissa's Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the dire need for change at Amarin Corporation plc (NASDAQ: AMRN) accessible at the link below: Presentation: https://freeamarin.com/wp-content/pdfs/vote-for-change.pdf Amarin shareholders face an important decision at our upcoming shareholder meeting.

Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa Capital is outraged but not surprised by Amarin's repeated false statements intended to mislead shareholders and switch votes away from Sarissa.

Sarissa Capital Blasts Amarin's Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board

Independent Report Acknowledges That Sarissa's Campaign to Remove Amarin's Chairman and De Facto Seize Board Control Would be Detrimental to Shareholder Value

Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote “AGAINST” Sarissa's Value-Destructive Proposals

Sarissa Issued its False Release Hours After Receiving Confirmation That All Proxy Cards Were Being Accepted Sarissa Issued its False Release Hours After Receiving Confirmation That All Proxy Cards Were Being Accepted

Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa Capital, in voting its shares, uncovered that Amarin's registrar, the firm retained by Amarin to receive and process proxy cards, had not been instructed to accept blue proxy cards even though legally required to do so. Amarin's registrar believed it was only authorized to accept and process the white proxy cards.

Sarissa Capital Uncovers That Amarin's Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So

Amarin Corporation plc (NASDAQ:AMRN ) SVB Securities Global Biopharma Conference February 14, 2023 10:40 AM ET Company Participants Karim Mikhail - President & CEO Tom Reilly - Chief Financial Officer Conference Call Participants Roanna Ruiz - SVB Securities Roanna Ruiz Great. Welcome back, everyone.

Amarin Corporation plc (AMRN) SVB Securities Global Biopharma Conference (Transcript)

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa Capital believes that today's Amarin webcast was yet again tone-deaf to shareholders and another display by management of a lack of accountability for its poor performance.

Sarissa Capital Disappointed That Amarin Webcast Continues Board's Defense of Poor Results and Lack of Accountability

Amarin (AMRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Amarin (AMRN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Glass Lewis Recognizes that Change Led by Amarin's New Board is Already Underway, and Sarissa Representation is Not Warranted

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote “AGAINST” All of Sarissa's Proposals

-- Board and Management Team to Answer Shareholder Questions -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that members of its Board of Directors and management team will host a live webcast on Tuesday, February 14, 2023, from 8:00 a.m. - 9:00 a.m. ET. The webcast will be a question-and-answer session where the Company will answer some of the most common shareholder questions focused on Amarin's strategy and what the refreshed Board and management team are doing to drive operational and financial improvements and enhance value for all shareholders.

Amarin Shareholders Invited to Webcast with Board and Management Team

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Amarin continues to waste precious shareholder capital in its self-serving attempts to keep shareholders out of the board room. Amarin has indicated that it will spend in excess of $7 MILLION to prevent Sarissa Capital, its largest shareholder, from obtaining representation on the board.

Sarissa Capital Warns of Amarin's Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following letter to other shareholders of Amarin Corporation plc (NASDAQ: AMRN): Dear Fellow Amarin Shareholders: We, the owners, face an important decision at our upcoming shareholder meeting. Amarin has an incredibly valuable asset in Vascepa/Vazkepa, but the company continues to destroy value by mismanagement and poor capital allocation decisions.

Sarissa Capital Does Not Believe Amarin Cares About Shareholders

Letter Underscores the Change That is Being Led by Amarin's New Board

Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa's Harmful Proposals

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN): Sarissa today released a presentation highlighting many of the inaccurate and misleading statements Amarin made in its attempts to thwart shareholder representation and oversight on the board. For Sarissa's presentation, please click on the link below. Presentation: https://freeamarin.com/wp-content/pdfs/presentation-slides-020723.

News for Amarin Corporation Plc Stock (AMRN)